LeonaBio (LONA) Operating Income (2019 - 2026)
LeonaBio (LONA) posted quarterly Operating Income of -$17.2 million for Q1 2026, down 80.52% year-over-year from -$88.3 million in Q1 2025, and up 78.09% quarter-over-quarter from -$78.6 million in Q4 2025.
LeonaBio (LONA) Operating Income (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Operating Income for 8 consecutive years, with -$17.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 80.52% year-over-year to -$17.2 million; the TTM figure through Mar 2026 stood at -$109.9 million (down 32.86% YoY), while the FY2025 annual figure was -$102.3 million, down 1.35% from the prior year.
- Operating Income improved to -$17.2 million in Q1 2026 per LONA's latest filing, from -$78.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$6.9 million in Q3 2025 and bottomed at -$78.6 million in Q4 2025.
- Historically, Operating Income has averaged -$26.5 million across 5 years, with a median of -$27.7 million in 2024.
- On a YoY basis, Operating Income climbed as much as 76.79% in 2025 and fell as far as 404.72% in 2025.
- LeonaBio's Operating Income stood at -$32.9 million in 2022, then increased by 11.88% to -$29.0 million in 2023, then jumped by 46.35% to -$15.6 million in 2024, then tumbled by 404.72% to -$78.6 million in 2025, then jumped by 78.09% to -$17.2 million in 2026.
- Business Quant data shows LONA's Operating Income at -$17.2 million in Q1 2026, -$78.6 million in Q4 2025, and -$6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | -19.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.21 Mn |
| Dec 31, 2025 | -78.57 Mn |
| Sep 30, 2025 | -6.87 Mn |
| Jun 30, 2025 | -7.29 Mn |
| Mar 31, 2025 | -9.54 Mn |
| Dec 31, 2024 | -15.57 Mn |
| Sep 30, 2024 | -29.62 Mn |
| Jun 30, 2024 | -28.03 Mn |
| Mar 31, 2024 | -27.69 Mn |
| Dec 31, 2023 | -29.01 Mn |
| Sep 30, 2023 | -35.04 Mn |
| Jun 30, 2023 | -31.64 Mn |
| Mar 31, 2023 | -29.77 Mn |
| Dec 31, 2022 | -32.93 Mn |
| Sep 30, 2022 | -24.13 Mn |
| Jun 30, 2022 | -23.57 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -18.78 Mn |
| Sep 30, 2021 | -17.83 Mn |
| Jun 30, 2021 | -16.64 Mn |